Glioblastomas are heterogeneous and invariably lethal tumours. They are characterized by
genetic and epigenetic variations among tumour cells, which makes the development of …

Extracellular vesicles (EVs) are a heterogeneous collection of membrane-bound carriers
with complex cargoes including proteins, lipids, and nucleic acids. While the release of EVs …

Despite an increasing arsenal of anticancer therapies, many patients continue to have poor
outcomes due to the therapeutic failures and tumor relapses. Indeed, the clinical efficacy of …

In recent years, the functions of glial cells, namely, astrocytes and microglia, have gained
prominence in several diseases of the central nervous system, especially in glioblastoma …

Cancer stem cells (CSCs), a minor subpopulation of tumor bulks with self-renewal and
seeding capacity to generate new tumors, posit a significant challenge to develop effective …

Glioblastoma (GBM) is one of the most lethal central nervous systems (CNS) tumours in
adults. As supplements to standard of care (SOC), various immunotherapies improve the …

Glioblastoma (GB) is the more frequent and malignant brain tumour. In spite of all efforts, the
median overall survival of GB patients remains approximately 15 months under therapy. The …

Glioblastoma is an aggressive tumor and is associated with a dismal prognosis. The
availability of few active treatments as well as the inexorable recurrence after surgery are …

Simple Summary Communication between cells helps tumors acquire resistance to
chemotherapy and makes the struggle against cancer more challenging. Tunneling …

Glioblastoma (GBM) recurrences are inevitable, and mainly originate from residual tumor
cells and the presence of glioma stem cells (GSC) around the resection cavity borders. We …